Although the PD-1/PD-L1 market is rapidly becoming saturated, with several drugs already approved and many more candidates undergoing clinical trials, ImmuneOncia Therapeutics, Inc. is challenging the space by targeting rare cancers of less interest to global big pharma firms, as well as cancers that have specific molecular signatures.
Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space
Pursues Two-Track Strategy
ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.
